remazolam
PreclinicalSmall molecule
remazolam is one of 29 small molecule programs targeting Delirium. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
167 competitors in Delirium
#DrugCompanyPhaseTrials
1Ritalin
NovartisPhase 3
Luvox
SSolvay Pharmaceuticals
Phase 3
IV Acetaminophen
AAFT Pharmaceuticals, Ltd.
Phase 3
Lidocaine IV
KKasr El Aini Hospital
Phase 3
Physostigmine
AstraZenecaPhase 3
Rozerem
TakedaPreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Anerem
AAcacia Pharma Ltd
Preclinical
Spravato
WWim Janssens
Preclinical
Raldesy
PPragma
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for remazolam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details